52 results about "Antibody mimetic" patented technology

Trifurcate RNA junction domains derived from phi29 pRNA are described that assemble with high affinity and that are stable in vitro and in vivo. Further expansion of trifurcated RNA domains to multiple way junction scaffolds via creative designs enable an array of toolkit to construct nanoparticle architectures with diverse shapes and angles. The scaffolds can be used to form RNA nanoparticles having a wide variety of uses, including promotion of RNA crystallization, creation of RNA aptamer with high affinity to mimic antibody, delivery of therapeutic and / or diagnostic agents such as biologically active RNA-based moieties, including siRNA, ribozymes, aptamers, and others.

The invention relates to a novel polypeptide for resisting tumors caused by EB (Epstein-Barr) viruses, and application and a preparation method thereof, belonging to the fields of antineoplastic medicaments. The novel polypeptide is composed of a colicine allosteric polypeptide capable of forming ion channels, and an antibody polypeptide for resisting EB viruses or a mimic antibody polypeptide ofan anti-EB virus antibody, wherein the colicine allosteric polypeptide capable of forming ion channels is formed by mutating amino acid residues G11A, H22G, A26G, V31L and H40D with wild type colicine E1, Ia, Ib, A, B and N or a peptide chain of aqueous pore canal domain thereof; and the amino acid sequence of the anti-EB virus antibody is identical to that of a monoclonal antibody secreted by ATCC HB-168 hybridoma. The invention provides an improved medicament, which has the advantages of strong lethality, high safety, high specificity and low sensitization possibility, for treating tumors caused by EB viruses, and a preparation method thereof.

The invention relates to a polymer for long-acting inhibition of HIV-1 membrane fusion. The polymer for long-acting inhibition of HIV-1 membrane fusion comprises two or three parts. The first part is a HIV-1 membrane fusion-inhibition polypeptide part and the second part is an antibody mimetic part capable of bonding with serum albumin thereby prolonging a half life of the polymer in vivo. A connection molecule can be arranged between the above two parts and improve HIV-1 inhibition activity of the polymer. The polymer can block virus-induced cell fusion in vivo for a long time.

The present invention provides a method of inhibiting HIV infection of a subject, comprising administering to the subject an effective amount of an antibody mimetic of carbohydrate binding module (CBM) which specifically binds to an epitope on HIV glycoprotein. The present invention also provides a pharmaceutical composition comprising a therapeutically or prophylactically effective amount of an antibody mimetic of carbohydrate binding module and a pharmaceutically acceptable carrier. The present invention also provides a method of inhibiting HIV infection of the subject preventionally or therapically comprising administering to the subject an effective amount of an antibody mimetic of carbohydrate binding module (CBM) which specifically binds to an epitope on HIV glycoprotein

Provided are compositions and methods for labeling an endogenous protein, in particular, in a live cell, or for ablating an endogenous or target protein. The compositions relate to a fusion protein having a binding moiety such as an antibody, an antigen binding fragment of an antibody or an antibody mimetic that recognizes the endogenous or target protein.

The present invention relates to the identification and use of antigen-binding regions, antibodies, antigen-binding antibody fragments and antibody mimetics, neutralizing the anti-coagulant effect of an anticoagulant in vitro and / or in vivo. Antibodies and functional fragments of the invention and antibody mimetics can be used to specifically reverse the pharmacological effect of an anticoagulant e.g. a FXa inhibitor for therapeutic (antidote) and / or diagnostic purposes. The invention also provides nucleic acid sequences encoding foregoing molecules, vectors containing the same, pharmaceutical compositions and kits with instructions for use.

The present invention relates to a method for identifying specific binding partners (e.g. antibodies or antibody mimetics) which bind to a desired target polypeptide. In particular, the method involves expressing a library of antibodies or antibody mimetics in a population of mammalian cells, wherein each cell in the population of cells displays the target polypeptide on the outer surface of the cell, and identifying or isolating cells within the population of cells to which antibodies or antibody mimetics are bound.

The present invention relates to compounds which function as antibody mimetic compounds. These compounds are bifunctional / multifunctional compounds which contain at least one cancer cell binding moiety which selectively binds to prostate specific membrane antigen (PSMA) and a FC receptor binding moiety which modulates an FC immune receptor, preferably a FcγRI receptor. Compounds according to the present invention bind selectively to cancer cells which upregulate PSMA and through that interaction, place the Fc receptor binding moiety of the compound in proximity to a Fc receptor, preferably a FcγRI receptor, which can modulate (preferably, upregulate) a humoral response in a patient to cancer cells. Through this biological action of the compounds according to the present invention, cancer cells, including metastatic cancer cells, especially prostate cancer cells can be immune regulated, resulting in the favorable therapy of cancer in a patient. Methods of using these compounds to treat cancer and / or reduce the likelihood of metastasis of cancer are additional aspects of the present invention.

The invention discloses a biotin-labeled polymer nanoparticle simulated antibody. The antibody refers to polymer nanoparticles prepared by simulating a molecular recognition mechanism between a Bt Cry1Ac protein and a brush border membrane receptor cadherin Bt-R1 in tobacco hornworms, and reacting a synthetic acrylamide-polypeptide-amide monomer and other coexistence monomers and biotin-labeled monomers. The polypeptide comprises an amino acid sequence NITIHITDTNNK, and the coexistence monomers refer to acrylamide and / or acrylate compounds. The invention further discloses a Bt enzyme-linked immunosorbent assay kit and a detection method established based on the biotin-labeled polymer nanoparticle simulated antibody. The Bt protein detected by the method is diversified in type, wide in application range, low in cost and small in workload. Meanwhile, the advantages of the traditional biological antibody based enzyme linked immunosorbent assay such as excellent specificity, high accuracyand simplicity and convenience in operation are remained, and the defects that the natural antibody is difficult to prepare, high in cost, poor in environmental tolerance, easy to inactivate and harshin preservation and reaction conditions and the like are overcome.

The present invention belongs to field of biology and medicine, and especially relates to a novel antibiotic comprising a mimetic antibody, its preparation methods and uses thereof. The novel antibiotic comprising comprising an antibody mimetic and a colicin,or comprising an antibody mimetic and a channel-forming domain of a colicin, the antibody mimetic covalently bonded to the carboxyl end of the polypeptide of the colicin or the channel-forming domain of the colicin, wherein the colicin is selected from a group consisting of colicin E1, Ia, Ib, A, B, N; wherein said antibody mimetic being yielded by fusing two complementarity determining regions (CDRs), V H CDR 1 ) and V L CDR through a cognate framework region (V H FR 2 ) of an immunoglobulin; wherein the immunoglobulin specifically recognizes bacterium porins. Its antibacterial ability is a thousandfold powerful than normal antibiotics. Due to its unique action mechanism, drug resistance resulted in mutation can hardly be acquired by pathogenic bacteria. And the antibiotic will not hurt normal human cells when it kills pathogenic bacteria. Therefore, it can be used for manufacturing antibacterial medicament of killing Diplococcus intracellularis, vancomycin-resistant enterococci, Methicillin-resistant Staphylococcus aureus, or multidrug resistant Pseudomonas aeruginosa.

The invention discloses a high-affinity anti-FGF-2 human-derived double-chain antibody with a stable disulfide bond and application. The human-derived double-chain antibody comprises a light-chain variable region shown as SEQ ID NO. 1 and a heavy-chain variable region shown as SEQ ID NO. 2. According to the high-affinity anti-FGF-2 human-derived double-chain antibody, a molecular structure is usedfor simulating a space structure of an antibody ds-Diabody and an antigen, and the stability is analyzed through thermodynamics; an antibody structure is optimized and modified to obtain the high-affinity anti-FGF-2 human-derived double-chain antibody with the stable disulfide bond; compared with an unmodified anti-FGF-2 human-derived ds-Diabody, the combination activity is improved by 3 times and the high-affinity anti-FGF-2 human-derived double-chain antibody with the stable disulfide bond has higher affinity; the antibody belongs to a small molecular antibody and has good tissue permeability; the disulfide bond is introduced so that the stability of the antibody can be improved; the antibody can be used for effectively inhibiting tumor angiogenesis and inhibiting the growth and transferring of tumors. Therefore, the human-derived double-chain antibody provided by the invention has a wide application prospect.

The present invention relates to the preparation of an antibody analogue capable of being activated reversibly, and uses thereof, and provides a fusion protein comprising an inactive first fragment of an antibody analogue is fused to a stimulus-induced dimerization protein.

The present invention features an antibody mimetic, or an antigen binding fragment thereof, that specifically binds to an allosteric site of Aurora A kinase, therapeutic compositions comprising this antibody mimetic, and the use of the monobody to modulate Aurora A kinase for the treatment of cancer.